<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is the <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesion</z:e> from which esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> near the esophagogastric junction arises </plain></SENT>
<SENT sid="1" pm="."><plain>The management of BE and the treatment of Barrett's esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (BEA) are important clinical issues in Europe and the United States </plain></SENT>
<SENT sid="2" pm="."><plain>As the <z:hpo ids='HP_0005202'>Helicobacter pylori infection</z:hpo> rate in Japan is decreasing in the younger population, the incidence of BE and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> arising from BE may start increasing </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, we review the current status of BEA and its management </plain></SENT>
<SENT sid="4" pm="."><plain>Magnifying endoscopy with narrow-band imaging is important for diagnosing <z:mpath ids='MPATH_589'>dysplasia</z:mpath> arising from BE </plain></SENT>
<SENT sid="5" pm="."><plain>In Japan, <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> arising from BE is managed the same way as <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> in the same location </plain></SENT>
<SENT sid="6" pm="."><plain>Strategies to prevent BEA may include medication such as <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> and <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi>, and anti-reflux surgery </plain></SENT>
<SENT sid="7" pm="."><plain>Understanding the pathophysiology of BE will help to reduce the incidence of BEA </plain></SENT>
</text></document>